J&J's Stelara Succeeds in Phase III Crohn's Disease TrialJ&J's Stelara Succeeds in Phase III Crohn's Disease Trial
Johnson & Johnson's Stelara (ustekinumab) was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
More News: Allergy | Allergy & Immunology | Crohn's Disease | Gastroenterology | Health | Inflammatory Bowel Disease | Stelara